Clinical Trials

AES does not endorse any of the clinical trials listed, but provides the information as a member service.

Despite the importance of birth control to women of reproductive age, there has been little formal investigation of the safety and effectiveness of birth control methods in women with epilepsy.  To remedy this, doctors from Harvard and Columbia University Medical Schools have developed a website that offers a survey to help us gain more knowledge and some educational material that will be updated regularly to provide the latest information.  The ultimate goal is to develop guidelines for the selection of safe and effective birth control methods and to make sure that the best forms of birth control become available to women with epilepsy in all communities of our society.  Take our survey and then catch up on the latest information about birth control for women with epilepsy.

  • Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (EQUIGEN Chronic-Dose Study)
    • Trial investigator(s) and contact information: PIs: Michael Privitera, MD; Michel Berg, MD 

    • Outcomes: Bioequivalence (AUC and Cmax differences) between “high” and “low” generic lamotrigine products chosen by ANDA data from FDA plus in vitro dissolution testing. Other outcomes include intra-subject variances and individual bioequivalence.

See EQUIGEN Announcement or for more information. 

From its start in 1992, GeneTests has grown to reflect the advances in genetic testing capabilities and to address the needs of our ever widening user community. We invite you to explore, try some of your favorite searches, and let us know what you think. Your feedback will help shape GeneTests into the indispensable tool you want for your practice.

  • HERO Website

Become a HERO. Take part in life-changing research.





The purpose of the HERO website is to make it easier for people to find and enroll in clinical studies and advance epilepsy research. The epilepsy community desperately needs new therapies and approaches for patients with resistant or refractory seizures. We need to know more about the basic mechanisms and causes of epilepsy so that we can better match therapies to patients, and someday soon find targets for cures. But none of these giant steps forward will be possible without robust, careful research that safeguards the health of study participants while uncovering important new findings.

It's your involvement helps researchers to ultimately uncover better ways to treat, prevent, diagnose and understand human disease. Read more.

  • PROSPER - Study

The PROSPER-1 Study will evaluate the safety and effectiveness of OXC XR as an adjunctive therapy at 1200mg/day and 2400mg/day in subjects diagnosed with partial seizures. This is a phase III study.

The goal of the Office of Rare Disorders at Vanderbilt is to provide a focal point for all Vanderbilt physicians, scientists, and clinical and translational investigators whose scientific and clinical practice entails caring for patients with rare disorders, and investigators seeking to discover the pathophysiology and treatment of these illnesses. Read more.